Clinical Trial

SUPRAFLEX CRUZ PMCF Study ( rEpic05 )

Study acronym: Multiflex
Recruiting
View on ClinicalTrials.gov →
Summary
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2022-11-08; most recent amendment 2025-12-15.
Status change: Not Yet Recruiting → Recruiting 2023-05-10
Trial Details
NCT Number NCT05617599
Lead Sponsor Fundación EPIC
Conditions Coronary Artery Disease (CAD), Ischemic Heart Disease
Enrollment 508 participants
Start Date 2023-05-10
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-16